MI-538

CAS No. 1857417-10-7

MI-538( MI538 | MI 538 )

Catalog No. M12867 CAS No. 1857417-10-7

MI-538 is potent and selective menin–MLL interaction inhibitor (IC50=21 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 213 Get Quote
10MG 375 Get Quote
25MG 627 Get Quote
50MG 893 Get Quote
100MG 1197 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MI-538
  • Note
    Research use only, not for human use.
  • Brief Description
    MI-538 is potent and selective menin–MLL interaction inhibitor (IC50=21 nM).
  • Description
    MI-538 is potent and selective menin–MLL interaction inhibitor (IC50=21 nM); shows the most potent binding affinity to menin (Kd = 6.5 nM) obtained for small molecule menin–MLL inhibitor reported to date; exhibits significantly increased activity, selectivity, polarity and pharmacokinetic profile over MI-136 and demonstrates a pronounced effect in a mouse model of MLL leukemia.
  • In Vitro
    MI-538 inhibits the proliferation of MLL leukemia cells with a GI50 of 83 nM. MI-538 shows no effect (up to 6 μM) on growth of the control cell lines HL-60 and HM-2, which do not harbor MLL translocations, demonstrating good selectivity toward MLL fusion protein transformed cells. MI-538 binds to menin with low nanomolar affinity (Kd=6.5 nM). Its potent cellular activity originates from the improved binding affinity to menin and possibly increased cell membrane permeability. Treatment with MI-538 results in strong down regulation of expression of Hoxa9 and Meis1 genes. About 100 nM 27 was sufficient to reduce by ~50% Hoxa9 expression in MLL-AF9 cells, and even more pronounced effect was seen on Meis1 expression.
  • In Vivo
    Treatment with MI-538 results in a pronounced, about 80%, reduction in the MV4;11 tumor volume, without causing substantial signs of toxicity reflected by less than 10% reduction of the body weight. MI-538 demonstrates markedly improved exposure (area under the curve, AUC, values), Cmax (maximum compound concentration) in the blood plasma, and the lowest value of clearance. The half-life of MI-538 is about 1.6 h. MI-538 has also high oral bioavailability (~50%).
  • Synonyms
    MI538 | MI 538
  • Pathway
    Chromatin/Epigenetic
  • Target
    HMTase
  • Recptor
    HMTase
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1857417-10-7
  • Formula Weight
    566.6006
  • Molecular Formula
    C27H25F3N8OS
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO; Need ultrasonic and warming
  • SMILES
    N#CC(N1CC2=CNN=C2)=CC3=C1C=C(O)C(CN4CCC(NC5=C(C=C(CC(F)(F)F)S6)C6=NC=N5)CC4)=C3
  • Chemical Name
    1H-Indole-2-carbonitrile, 6-hydroxy-1-(1H-pyrazol-4-ylmethyl)-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]-1-piperidinyl]methyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Borkin D, et al. J Med Chem. 2016 Feb 11;59(3):892-913.
molnova catalog
related products
  • PF-06726304

    PF-06726304 is a novel potent enhancer of zeste homolog 2 (EZH2) inhibitor.

  • EPZ020411 dihydrochl...

    EPZ020411 is a potent, selective PRMT6 inhibitor with IC50 of 10 nM, displays 10-fold and 20-fold selectivity over PRMT1/8.

  • UNC3866

    A potent, selective PRC1 chromodomains antagonist that binds to CBX4 and CBX7 with Kd of 100 nM.